The Performance and Benefits of Cardiovascular Drugs Market: Analysis, Growth, and Trends

According to a new report published by Reports Monitor titled, “Cardiovascular Drugs Market by drug, disease, distribution channel: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the Cardiovascular Drugs Market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. North America is anticipated to dominate the market and is expected to maintain leading position throughout the forecast period.

Cardiovascular drugs are primarily used in order to treat diseased condition associated with function & structure of blood vessels and heart.  Commonly occurring cardiovascular diseases include coronary artery diseases, peripheral artery disease, thrombosis, asischemic, thrombosis, stroke and others. Root cause of cardiovascular diseases include absence of physical activity, stoutness, smoking, high consumption of liquor and terrible routine habits. Large ranges of remedies are recommended to cure the condition.

Get Sample Copy for more Professional and Technical insights @

Cardiovascular Drug Market 2025
Cardiovascular Drug Market 2025

As per world health organization estimates CVD is culpable for near about 15 million deaths around the world every year. Primary drivers for the market includes rising geriatric population associated with diabetes and heart disorders, supportive government activities and increase in medical spending per capta. Moreover, unique mechanisms of action of therapeutics along with advanced combine therapies boost the market to grow further. Nevertheless, stringent FDA guidelines and huge cost required for drug development are likely to restrict the market growth. Number of cardiovascular medicine patent getting expired offers constructive opportunities to the vendors to develop ingenious medication.

As compared to anti-thrombotic and hypolipidemics anti-hypertensive drug market holds the largest share of the market owing to presence of multibillion drugs. Currently, an anti-thrombotic segment account for small market share however is anticipated to grow during forecast period. Based on distribution channel hospital pharmacy section is dominating owing to high occurrence of emergency department and hospital visits.

View Full Press Release @

Key Findings and Scope:
• Globally North America ruled the cardiovascular drug market in 2013 due to high awareness related to heart disorders.
• As per American Heart Association (AHA), in 2013, cardiovascular illnesses represented more than 17.3 million passing all around, representing 31% of all global deaths.
• The worldwide number is required to ascend to 23.6 million by 2030. In 2010, the worldwide weight of cardiovascular ailments was US$ 863 billion, and it is required to ascend to US$1044 billion by 2030.

The major companies profiled in the report include Merck & Co., Sanofi, Pfizer, Medicure Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly, Johnson & Johnson, AstraZeneca PLC, Abbott Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd.

About Us:
Garner Insights ( is a Market Intelligence and Business Consulting firm led by professionals with a vast experience and knowledge of the market research industry.

Our vast repository of research reports across various categories gives you a complete view of the ever-evolving trends and current topics worldwide. Our constant focus is on improving the data and finding innovative methods, which will help your business drive profitable growth.

The research methodology is designed to cater all your research needs which is backed by exclusive quantitative and analytics-driven intelligence. It consists of primary and secondary methods which is a testimony of the information comprised. The meticulous and distinct data gathering methods are in line with the highest standards of data mining in the industry.

We have a plethora bank of publishers who share their various quality reports using our platform and expertise. The data bank is monitored by the team of experts which is validated by various statistical data and trending content.

Contact Us:
Mr. Kevin Thomas
+1 513 549 5911 (US)
+44 203 318 2846 (UK)

Leave a Reply

Your email address will not be published. Required fields are marked *